L718Q Mutant EGFR Escapes Covalent Inhibition by Stabilizing a Non-reactive Conformation of the Lung Cancer Drug Osimertinib

Overview

Journal Chem Sci

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2018 May 8

PMID 29732058

Citations 32

Authors

D Callegari

K E Ranaghan

C J Woods

R Minari

M Tiseo

M Mor

A J Mulholland

A Lodola

Affiliations

Soon will be listed here.

Abstract

Osimertinib is a third-generation inhibitor approved for the treatment of non-small cell lung cancer. It overcomes resistance to first-generation inhibitors by incorporating an acrylamide group which alkylates Cys797 of EGFR T790M. The mutation of a residue in the P-loop (L718Q) was shown to cause resistance to osimertinib, but the molecular mechanism of this process is unknown. Here, we investigated the inhibitory process for EGFR T790M (susceptible to osimertinib) and EGFR T790M/L718Q (resistant to osimertinib), by modelling the chemical step (, alkylation of Cys797) using QM/MM simulations and the recognition step by MD simulations coupled with free-energy calculations. The calculations indicate that L718Q has a negligible impact on both the activation energy for Cys797 alkylation and the free-energy of binding for the formation of the non-covalent complex. The results show that Gln718 affects the conformational space of the EGFR-osimertinib complex, stabilizing a conformation of acrylamide which prevents reaction with Cys797.

Citing Articles

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Liao Y, Tsai C, Huang H Cancers (Basel). 2025; 17(3).

PMID: 39941826 PMC: 11815769. DOI: 10.3390/cancers17030459.

QM/MM simulations of EFGR with afatinib reveal the role of the -dimethylaminomethyl substitution.

Ma S, Patel H, Peeples C, Shen J bioRxiv. 2024; .

PMID: 38766221 PMC: 11100610. DOI: 10.1101/2024.02.18.580887.

Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity.

Guidetti L, Zappia A, Scalvini L, Ferrari F, Giorgio C, Castelli R J Chem Inf Model. 2023; 63(21):6900-6911.

PMID: 37910792 PMC: 10647059. DOI: 10.1021/acs.jcim.3c01064.

Recent Development in the Search for Epidermal Growth Factor Receptor (EGFR) Inhibitors based on the Indole Pharmacophore.

Mishra S, Sahu A, Kaur A, Kaur M, Kumar J, Wal P Curr Top Med Chem. 2023; 24(7):581-613.

PMID: 37909440 DOI: 10.2174/0115680266264206231020111820.

EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer.

Wu P, Lin M, Hsiao J, Lin P, Pan S, Chen Y Mol Cell Proteomics. 2023; 22(9):100624.

PMID: 37495186 PMC: 10545940. DOI: 10.1016/j.mcpro.2023.100624.

References

Carmi C, Lodola A, Rivara S, Vacondio F, Cavazzoni A, Alfieri R . Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. Mini Rev Med Chem. 2011; 11(12):1019-30. DOI: 10.2174/138955711797247725. View

Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2000; 103(2):211-25. DOI: 10.1016/s0092-8674(00)00114-8. View

Anandakrishnan R, Aguilar B, Onufriev A . H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res. 2012; 40(Web Server issue):W537-41. PMC: 3394296. DOI: 10.1093/nar/gks375. View

Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A . LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013; 31(27):3335-41. DOI: 10.1200/JCO.2012.45.0981. View

Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A . L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. J Thorac Oncol. 2016; 11(10):e121-3. DOI: 10.1016/j.jtho.2016.05.019. View

Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C . Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006; 65(3):712-25. PMC: 4805110. DOI: 10.1002/prot.21123. View

Wang J, Wolf R, Caldwell J, Kollman P, Case D . Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. DOI: 10.1002/jcc.20035. View

Olsson M, Sondergaard C, Rostkowski M, Jensen J . PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. J Chem Theory Comput. 2015; 7(2):525-37. DOI: 10.1021/ct100578z. View

Ercan D, Choi H, Yun C, Capelletti M, Xie T, Eck M . EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res. 2015; 21(17):3913-23. PMC: 4791951. DOI: 10.1158/1078-0432.CCR-14-2789. View

10.

Gruden M, Andjeklovic L, Jissy A, Stepanovic S, Zlatar M, Cui Q . Benchmarking density functional tight binding models for barrier heights and reaction energetics of organic molecules. J Comput Chem. 2017; 38(25):2171-2185. PMC: 5554453. DOI: 10.1002/jcc.24866. View

11.

Woods C, Malaisree M, Hannongbua S, Mulholland A . A water-swap reaction coordinate for the calculation of absolute protein-ligand binding free energies. J Chem Phys. 2011; 134(5):054114. DOI: 10.1063/1.3519057. View

12.

Yosaatmadja Y, Silva S, Dickson J, Patterson A, Smaill J, Flanagan J . Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. J Struct Biol. 2015; 192(3):539-544. DOI: 10.1016/j.jsb.2015.10.018. View

13.

Yan X, Zhu S, Liang L, Zhao P, Choi H, Yun C . Structural basis of mutant-selectivity and drug-resistance related to CO-1686. Oncotarget. 2017; 8(32):53508-53517. PMC: 5581126. DOI: 10.18632/oncotarget.18588. View

14.

Berteotti A, Vacondio F, Lodola A, Bassi M, Silva C, Mor M . Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. ACS Med Chem Lett. 2014; 5(5):501-5. PMC: 4027605. DOI: 10.1021/ml400489b. View

15.

Lodola A, De Vivo M . The increasing role of QM/MM in drug discovery. Adv Protein Chem Struct Biol. 2012; 87:337-62. DOI: 10.1016/B978-0-12-398312-1.00011-1. View

16.

Madzelan P, Labunska T, Wilson M . Influence of peptide dipoles and hydrogen bonds on reactive cysteine pKa values in fission yeast DJ-1. FEBS J. 2012; 279(22):4111-20. PMC: 3484204. DOI: 10.1111/febs.12004. View

17.

Flanagan M, Abramite J, Anderson D, Aulabaugh A, Dahal U, Gilbert A . Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J Med Chem. 2014; 57(23):10072-9. DOI: 10.1021/jm501412a. View

18.

Engel J, Lategahn J, Rauh D . Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer. ACS Med Chem Lett. 2016; 7(1):2-5. PMC: 4716607. DOI: 10.1021/acsmedchemlett.5b00475. View

19.

Finlay M, Anderton M, Ashton S, Ballard P, Bethel P, Box M . Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014; 57(20):8249-67. DOI: 10.1021/jm500973a. View

20.

Pan L, Song L, Miao Y, Yang Y, Merz Jr K . Mechanism of Formation of the Nonstandard Product in the Prenyltransferase Reaction of the G115T Mutant of FtmPT1: A Case of Reaction Dynamics Calling the Shots?. Biochemistry. 2017; 56(24):2995-3007. DOI: 10.1021/acs.biochem.7b00248. View